Thermo Fisher Scientific (TMO) Said to Make $30B Offer to Acquire Illumina (ILMN) - Source
- Stocks dip as earnings pour in, consumer discretionary lags
- UPDATE: Alphabet (GOOG) Tops Q3 EPS Views; Revs Strong
- Twitter (TWTR) Tops Q3 EPS by 4c; Announces Restructuring, Workforce Reduction
- Cirrus Logic, Inc. (CRUS) Q2 Results and Guidance Beat Estimates
- Amazon.com (AMZN) Misses Q3 EPS by 26c, Offers Q4 Guidance
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Illumina (Nasdaq: ILMN), a San Diego-based company specializing in DNA sequencing and array-based technologies, is said to have received a $30 billion acquisition proposal from Thermo Fisher Scientific (NYSE: TMO), according to a source claiming to have knowledge of the matter.
The proposed deal -- potentially one of the largest of the year – would be a stock for stock transaction without a cash component, the person said.
In 2012, Illumina successfully rebuffed a hostile bid from Roche (OTC: RHHBY) and recent rumors have suggested Roche might renew these efforts. The topic was discussed recently on M&A blog Betaville. If the rumor is accurate, a bid from Thermo Fisher would undoubtedly add a new dimension to the story.
JP Morgan and Merrill Lynch are said be acting as advisors in the deal.
Representatives from Illumina and Thermo Fisher haven’t responded to requests for comment.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Sanchez Energy (SN) in Talks to Partner with Blackstone (BX) on Deal for Anadarko Petroleum (APC) South Texas Assets - DJ
- TGP Exits $2B Race for McDonald's (MCD) China Business - Bloomberg
- UPDATE: Gannett (GCI) -Tronc (TRNC) deal still in doubt as banks said to withdraw financing
Create E-mail Alert Related CategoriesHot M&A, Mergers and Acquisitions, Rumors, Trader Talk
Related EntitiesJPMorgan, Merrill Lynch, Definitive Agreement
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!